Orphan Drug Designation
A special regulatory status for drugs treating rare diseases (fewer than 200,000 US patients or fewer than 5 in 10,000 EU). Orphan designation provides incentives including market exclusivity (7 years US, 10 years EU), tax credits, and fee waivers. Setmelanotide, trofinetide, and teduglutide hold orphan designations.
Technical Context
US orphan designation (FDA Office of Orphan Products Development): prevalence <200,000 US patients OR no reasonable expectation of cost recovery. Benefits: 7-year market exclusivity, 25% tax credit on clinical trial costs, waiver of PDUFA fees (~$4M savings), FDA orphan grants programme (up to $600K/year for clinical trials). EU orphan designation (EMA COMP): prevalence <5/10,000 EU population AND no satisfactory treatment exists. Benefits: 10-year market exclusivity, protocol assistance (scientific advice at reduced fee), EMA fee reductions. Peptide examples: setmelanotide (POMC/PCSK1/LEPR deficiency obesity — ultra-rare), trofinetide (Rett syndrome — ~1:10,000-15,000 female births), teduglutide (short bowel syndrome — ~10,000-20,000 US patients), elamipretide (Barth syndrome — ~1:300,000-400,000 births), vosoritide (achondroplasia — ~1:15,000-40,000 births).